VolitionRx Validates Automated Cancer Test for Pets in Japanese Veterinary Market

VolitionRx Limited has announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan. This development enables full automation in central laboratories through the IDS i10 automated analyzer platform. The transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows. More than 1,700 veterinary hospitals in Japan are already registered to use the test, indicating significant existing adoption.

The company highlighted Japan's approximately seven million pet dogs as a key market for the automated test. The automated platform aligns with the same system used for Volition's human diagnostic products, including Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover. This cross-platform synergy represents a strategic advantage for the company's broader diagnostic portfolio. The validation represents a significant step in expanding access to cancer detection for companion animals through laboratory automation.

Volition is a multi-national company focused on advancing the science of epigenetics through blood tests designed to detect and monitor diseases. The company maintains research and development activities in Belgium with additional facilities in the United States and United Kingdom. For further information about the company's work, visit https://volition.com/. The press release detailing this announcement can be accessed at https://ibn.fm/k076y.

The automation validation addresses a growing need in veterinary medicine for efficient diagnostic tools. Faster processing capabilities could lead to more timely interventions for pets suspected of having cancer. The scale of Japan's pet population creates substantial potential for the test's utilization across veterinary practices. The integration with existing human diagnostic systems suggests potential operational efficiencies for laboratories running both human and animal tests.

This development comes as the veterinary diagnostics market continues to expand globally. Automated testing platforms typically reduce human error and increase consistency in test results. The validation with Fujifilm Vet Systems represents a partnership that facilitates market entry and distribution within Japan. The existing network of registered veterinary hospitals provides an immediate pathway for test implementation following the automation milestone.